Tenon Medical Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
TNON$1.75+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Unaudited)
(In thousands, except share data)
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $9,162 | $2,428 |
| Accounts receivable, net | 876 | 518 |
| Inventory | 607 | 554 |
| Prepaid expenses and other current assets | 543 | 389 |
| Total current assets | 11,188 | 3,889 |
| Fixed assets, net | 906 | 961 |
| Deposits | 51 | 51 |
| Operating lease right-of-use asset | 463 | 646 |
| Deferred offering costs | 431 | 798 |
| TOTAL ASSETS | $13,039 | $6,345 |
| Liabilities and Stockholders’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,093 | $433 |
| Accrued expenses | 908 | 808 |
| Current portion of accrued commissions | 898 | 470 |
| Current portion of operating lease liability | 279 | 256 |
| Convertible notes payable and accrued interest, net of debt discount of $0 and $77 at September 30, 2024 and December 31, 2023, respectively | — | 1,173 |
| Total current liabilities | 3,178 | 3,140 |
| Accrued commissions, net of current portion | 1,454 | 1,999 |
| Operating lease liability, net of current portion | 216 | 428 |
| Total liabilities | 4,848 | 5,567 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at September 30, 2024 and December 31, 2023; 256,968 and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 3,300 | — |
| Series B convertible preferred stock, $0.001 par value; 491,222 shares authorized at September 30, 2024 and December 31, 2023; 86,454 and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 452 | — |
| Common stock, $0.001 par value; 130,000,000 shares authorized at September 30, 2024 and December 31, 2023; 3,136,013 and 325,039 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 3 | — |
| Additional paid-in capital | 70,095 | 55,897 |
| Accumulated deficit | (65,659) | (55,073) |
| Accumulated other comprehensive loss | — | (46) |
| Total stockholders’ equity | 8,191 | 778 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $13,039 | $6,345 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.